plus 2, Chemicals suspected in breast cancer - Bangkok Post |
- Chemicals suspected in breast cancer - Bangkok Post
- Latinas And Breast Cancer Target Of Major International Study With $1 ... - Medical News Today
- European regulators give greenlight to Glaxo's kidney and breast cancer drugs - Washington Examiner
| Chemicals suspected in breast cancer - Bangkok Post Posted: 20 Feb 2010 10:03 AM PST Message from fivefilters.org: If you can, please donate to the full-text RSS service so we can continue developing it. US experts called for toxicity tests on chemicals they suspect play a role in the development of breast cancer, a leading cause of death in American women. An Indian woman attends a breast cancer screening intiative in Hyderabad. US experts called Friday for toxicity tests on chemicals they suspect play a role in the development of breast cancer, a leading cause of death in American women. "We're currently not identifying chemicals that could be contributing to the risk of breast cancer," said Megan Schwarzman, a physician and environmental health researcher at the University of California, Berkeley. According to Schwarzman, only a handful of the more than 200 chemicals in the environment linked to mammary tumours in lab animals have been regulated by the US authorities "on the basis of their ability to cause breast cancer." She was speaking at a major science gathering, the annual meeting of the American Association for the Advancement of Science in San Diego. Schwarzman is part of a panel of experts set up last year to identify which chemicals cause breast cancer and to develop toxicity tests to identify them. The Breast Cancer Chemical Policy Project is expected to submit a report to health authorities in April. As the incidence of the most common invasive cancer in women has skyrocketed in a generation, a flurry of studies have looked into the role of chemicals in breast cancer. Treatment and survival rates have improved, but scientists have been running to stand still when it comes to pinpointing what causes breast cancer, said panel member Sarah Janssen, a physician and scientist with the Natural Resources Defence Council. "Although we've made great strides in improving treatment and breast cancer survival rates, really we don't know much about preventing breast cancer... and most of the causes are not well understood," she said, noting hypotheses that environmental exposure affects breast development and the risk of disease. "People are exposed to dozens of chemicals in their daily activities and biomonitoring has detected hundreds of chemicals in the fetal cord blood, in breast milk, adult blood and urine." Only around a quarter of more than 186,000 women diagnosed with breast cancer in 2005 were genetically predisposed to the disease, and other breast cancer risk factors, including the early onset puberty in girls, have been linked to chemicals. Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| Latinas And Breast Cancer Target Of Major International Study With $1 ... - Medical News Today Posted: 19 Feb 2010 05:57 PM PST Message from fivefilters.org: If you can, please donate to the full-text RSS service so we can continue developing it. Main Category: Breast Cancer Also Included In: Cancer / Oncology Article Date: 19 Feb 2010 - 18:00 PST
The largest study ever of breast cancer in Latin American women is being launched this year in a unique multi-country, public/private partnership with $1 million in additional funding from the world's largest breast cancer organization, Susan G. Komen for the Cure®. Spearheaded by the National Cancer Institute (NCI) Office of Latin American Cancer Program Development, the partnership signed today will support the development of programs for cancer research, clinical trials, training programs, technology and capacity building in five Latin American countries, with implications for Latinas in the United States and globally. "Breast cancer is a leading cause of death in Latinas here in the United States and around the world, and requires a large-scale effort to address and overcome," said Nancy G. Brinker, founder and CEO of Komen for the Cure. "This landmark collaboration between Komen, NCI, and five Latin American countries will help us get to answers about genetics, environment and social issues that contribute to breast cancer deaths in Latinas." "Importantly," Brinker said, "They will also help us develop strategies to reduce breast cancer incidence and death in this large and growing group -- both in Latin American countries and among Hispanic populations here in the U.S." The research will be conducted in Argentina, Brazil, Chile, Mexico and Uruguay. Brinker and NCI Director, John E. Niederhuber, M.D., signed an agreement for funding today in a ceremony in Washington, D.C. This follows the signing of bilateral agreements among the five countries and the NCI last fall. The Latin American countries and the United States will link their research efforts through the cancer Biomedical Informatics Grid, an information network that allows researchers to share data and knowledge. They also will develop pilot projects to enhance research and improve delivery of cancer treatments to patients in the United States and Latin America. This is the first major multi-country research effort specifically aimed at women in Latin American countries. A crucial first step is building the information database to identify breast cancer patterns in Latin women. "Clearly, making continued progress against cancer in the United States, and certainly across the globe, will require many resources, both public and private. For this initiative, we are most grateful for the generous support of Susan G. Komen for the Cure," Niederhuber said. "Not only is it crucial that we understand cancer incidence and trends in different countries; newfound genetic, genomic, and population-based knowledge will help elucidate the origins of breast cancer in Hispanic women from all of our nations." From there, the project will develop strategies for improved breast cancer detection, management and treatment in Latin America, enhanced research training and developing a clinical research infrastructure for the future. An estimated 14,000 cases of breast cancer were diagnosed in U.S. Hispanic women in 2009, with more than 2,200 deaths, making breast cancer the leading cause of cancer death among Latina women in the U.S. Breast cancer in Latinas is more often diagnosed at a later stage (when the disease is more advanced) than when found in non-Hispanic women. Cancer incidence in Latin American countries continues to rise, according to NCI, and takes a large toll on Hispanic/Latino populations in the United States. It is estimated that the U.S. Hispanic population will climb to nearly 60 million and represent approximately 19 percent of the U.S. population by 2020. Reducing the burden of cancer in the United States and abroad will depend heavily on understanding and controlling cancer in this population. Source Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. This posting includes an audio/video/photo media file: Download Now |
| European regulators give greenlight to Glaxo's kidney and breast cancer drugs - Washington Examiner Posted: 19 Feb 2010 07:27 AM PST Message from fivefilters.org: If you can, please donate to the full-text RSS service so we can continue developing it. LONDON — European regulators on Friday recommended GlaxoSmithKline PLC's kidney cancer drug Votrient for conditional marketing authorization and also backed the wider use of the company's breast cancer drug Tyverb. Decisions by the European Medicines Agency are usually endorsed formally by the European Commission, the European Union's executive body, within a couple of months. The conditional decision on Votrient, which is designed to treat advanced renal cell carcinoma, means that it will be reviewed by the EMA in a year. The agency has said it wants to see a comparison with Pfizer's Sutent. The EMA said that Tyverb, which is sold as Tykerb in the United States, should be approved for use in combination with an aromatase inhibitor in some breast cancer patients.
' + timeStamp + ' ' + comment + ' ';
commentSection.appendChild(commentDiv);
//setTimeout('location.href="http://www.washingtonexaminer.com/economy/european-regulators-give-greenlight-to-glaxos-kidney-and-breast-cancer-drugs-84774107.html?c=y"', 2000);
}
}
}
function fixCommentBody(form){
var fieldBody = document.getElementById("field.body")
var bodyValue = fieldBody.value;
bodyValue = bodyValue.replace(/&/g,"&");
bodyValue = bodyValue.replace(/,"/g,">");
bodyValue = bodyValue.replace(/\r\n/g," Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| You are subscribed to email updates from Add Images to any RSS Feed To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google Inc., 20 West Kinzie, Chicago IL USA 60610 | |
